Kelsey Stephen Michael 4
4 · Revolution Medicines, Inc. · Filed Jun 18, 2026
Research Summary
AI-generated summary of this filing
Revolution Medicines (RVMD) President Kelsey Michael Sells Shares
What Happened Kelsey Stephen Michael, President, Research and Development at Revolution Medicines (RVMD), sold 4,175 shares on June 16, 2026 in an open-market/private sale for a weighted average price of $156.12, generating about $651,798. The trades were executed under a previously adopted Rule 10b5-1 plan to satisfy tax withholding obligations tied to RSU vesting.
Key Details
- Transaction date: 2026-06-16; Form 4 filed 2026-06-18 (timely).
- Shares sold: 4,175; weighted average price: $156.12; reported total proceeds ≈ $651,798.
- Execution details: multiple trades at prices ranging $156.1105 to $156.8250 (weighted avg reported); reporting person will provide full trade-by-trade info upon request (per filing).
- Footnotes: Sale made pursuant to a 10b5-1 instruction adopted May 31, 2023 to cover tax withholding on RSU vesting after July 15, 2023.
- Holdings noted in filing: includes 76,251 RSUs and 653 shares from the Employee Stock Purchase Plan (ESPP). The report excerpt does not list a single consolidated "shares owned after transaction" total.
- Role: President, Research and Development (reported in Remarks).
Context
- This was a sale executed under a prearranged 10b5-1 plan to satisfy tax-withholding related to restricted stock unit vesting; such transactions are typically routine and done for tax/accounting reasons rather than a direct signal about the insider’s view of the company.
- No options exercise or gift reported in this transaction. The filing does not indicate the reporting person is a 10% owner.
Insider Transaction Report
Form 4
Kelsey Stephen Michael
See Remarks
Transactions
- Sale
Common Stock
[F1][F2][F3][F4]2026-06-16$156.12/sh−4,175$651,798→ 291,876 total
Footnotes (4)
- [F1]Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.
- [F2]This transaction was executed in multiple trades at prices ranging from $156.1105 to $156.8250. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]Includes 76,251 RSUs.
- [F4]Includes 653 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026.
Signature
/s/ Jack Anders, as Attorney-in-fact for Stephen Michael Kelsey|2026-06-18